We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Cancer Biomarkers Identify Candidates for Aggressive Treatment

By LabMedica International staff writers
Posted on 26 Jan 2017
Print article
Image: A histopathology of prostate cancer – The presence of luminal comedo necrosis in a cancer gland space is sufficient to diagnose Gleason grade 5 (Photo courtesy of Kenneth Iczkowski, MD).
Image: A histopathology of prostate cancer – The presence of luminal comedo necrosis in a cancer gland space is sufficient to diagnose Gleason grade 5 (Photo courtesy of Kenneth Iczkowski, MD).
Prostate cancer (PC) is the second leading cause of male cancer death in the USA with an estimated 26,000 deaths in 2016. Two-thirds of all PC deaths observed in the US are men with localized disease who developed metastasis.

Several biomarkers for dying from prostate cancer exist, but whether these are markers for telling who is likely to die early from any cause, and how their performance compares, is unknown. Identifying such a marker is important because physicians can then identify which men may benefit from new, more aggressive treatments for prostate cancer.

Oncologists at the Brigham and Women’s Hospital and their colleagues conducted a randomized clinical trial of 206 men with unfavorable-risk prostate cancer who were seen at a Harvard-affiliated academic hospital or an associated community hospital between December 1, 1995, to April 15, 2001.The men were identified, randomized to radiation therapy alone or radiation therapy followed by six months of androgen deprivation therapy, and followed for a median 16.62 years. A subgroup of 157 men with minimal comorbidities or no comorbidity were analyzed.

The team ascertained and compared the performance of four candidate surrogates (prostate-specific antigen [PSA] failure, PSA nadir greater than 0.5 ng/mL, PSA doubling time less than nine months, and interval to PSA failure (less than 30 months) for all-cause mortality using the proportion of treatment-effect metric. The investigators found that a prostate specific antigen (PSA) nadir (the lowest level a PSA drops after treatment) greater than 0.5 ng/mL following radiation and androgen deprivation therapy (anti-hormone therapy), appears to identify men prior to PSA failure who are at high-risk for dying early as a result of treatment failure for their prostate cancer.

Anthony Victor D'Amico, MD, PhD, chief of Genitourinary Radiation Oncology, and the senior author of the study, said “This study's results can have practice changing implications on how future prostate cancer trials are designed in terms of identifying the men for these studies who are at high risk for early death due to ineffective initial treatment for their prostate cancer.” The study was published on January 12, 2017, in the journal JAMA Oncology.

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.